Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor James Hildreth tells us about Immunology in Oxford at the end of the 1970s and the beginning of the 1980s when he started a DPhil project as a Rhode Scholar. Professor Hildreth worked on the debate of Altered Self vs Dual Recognition, using a new tool at the time, monoclonal antibodies.

Professor Hildreth then moved on from flu to working on HIV. His work has been focussing on the first steps (attachment) and final steps (budding and assembly) of the HIV-1 replication cycle.

Professor James Hildreth


james-headshotProfessor James Hildreth is Dean of the University of California–Davis, College of Biological Sciences. After graduating from Harvard, James Hildreth attended the University of Oxford as a Rhode Scholar, and earned a DPhil in Immunology in 1982. Professor Hildreth began research on HIV and AIDS in 1986 and his work has since focused on how HIV penetrates the cell and promotes infection. After discovering that cholesterol actively enables HIV to enter cells, Professor Hildreth’s research group found that eliminating fatty matter from a cell’s membrane might stop infection. Hildreth’s team have since developed topical microbicides, generally known as 'chemical condoms', to block the sexual transmission of the virus.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.